MA45069A - Protéines agonistes du récepteur trail monocaténaires - Google Patents

Protéines agonistes du récepteur trail monocaténaires

Info

Publication number: MA45069A
Authority: MA; Morocco
Prior art keywords: catenary; agonist proteins; trail; receiver agonist; trail receiver
Prior art date: 2014-04-23

Application number

MA045069A

Other languages

English (en)

Inventor

Fritz G Buchanan

Christian Gieffers

Oliver Hill

Susan E Lappe

Darren C Phillips

Meinolf Thiemann

Original Assignee

Abbvie Inc

Apogenix Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-04-23

Filing date

2015-04-23

Publication date

2019-04-03

2015-04-23 Application filed by Abbvie Inc, Apogenix Ag filed Critical Abbvie Inc

2019-04-03 Publication of MA45069A publication Critical patent/MA45069A/fr

Links

239000000556 agonist Substances 0.000 title 1
102000004169 proteins and genes Human genes 0.000 title 1
108090000623 proteins and genes Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Cell Biology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Psychiatry (AREA)
Transplantation (AREA)

MA045069A 2014-04-23 2015-04-23 Protéines agonistes du récepteur trail monocaténaires MA45069A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201461983152P	2014-04-23	2014-04-23

Publications (1)

Publication Number	Publication Date
MA45069A true MA45069A (fr)	2019-04-03

Family

ID=53055121

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA039770A MA39770A (fr)	2014-04-23	2015-04-23	Protéines agonistes du récepteur trail monocaténaires
MA045069A MA45069A (fr)	2014-04-23	2015-04-23	Protéines agonistes du récepteur trail monocaténaires

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
MA039770A MA39770A (fr)	2014-04-23	2015-04-23	Protéines agonistes du récepteur trail monocaténaires

Country Status (38)

Country	Link
US (5)	US9908927B2 (fr)
EP (2)	EP3366699A1 (fr)
JP (2)	JP6523331B2 (fr)
KR (2)	KR102079919B1 (fr)
CN (2)	CN106459221B (fr)
AR (1)	AR100168A1 (fr)
AU (3)	AU2015249649B2 (fr)
BR (1)	BR112016024515B1 (fr)
CA (2)	CA2946402C (fr)
CL (1)	CL2016002683A1 (fr)
CR (1)	CR20160516A (fr)
CY (1)	CY1120281T1 (fr)
DK (1)	DK3134430T3 (fr)
DO (1)	DOP2016000284A (fr)
EC (1)	ECSP16089579A (fr)
ES (1)	ES2672368T3 (fr)
HR (1)	HRP20180950T1 (fr)
HU (1)	HUE038914T2 (fr)
IL (2)	IL248244B (fr)
LT (1)	LT3134430T (fr)
MA (2)	MA39770A (fr)
MX (2)	MX2016013858A (fr)
MY (1)	MY181986A (fr)
NO (1)	NO2776305T3 (fr)
PE (1)	PE20170299A1 (fr)
PH (2)	PH12020500377A1 (fr)
PL (1)	PL3134430T3 (fr)
PT (1)	PT3134430T (fr)
RS (1)	RS57153B1 (fr)
RU (1)	RU2699285C2 (fr)
SG (3)	SG11201608767XA (fr)
SI (1)	SI3134430T1 (fr)
SM (1)	SMT201800286T1 (fr)
TR (1)	TR201806912T4 (fr)
TW (2)	TWI747178B (fr)
UA (1)	UA118286C2 (fr)
UY (1)	UY36095A (fr)
WO (1)	WO2015164588A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112017023646A2 (pt) *	2015-05-04	2018-07-17	Apogenix Ag	proteínas agonistas de receptor de cd40 de cadeia simples
EP3364995B1 (fr)	2015-10-23	2021-08-04	Apogenix AG	Protéines agonistes du récepteur cd27 à chaîne unique
JP6873119B2 (ja) *	2015-10-23	2021-05-19	アポジェニックスアーゲー	一本鎖ｌｉｇｈｔ受容体アゴニストタンパク質
EP3365363A1 (fr) *	2015-10-23	2018-08-29	Apogenix AG	Protéines agonistes du récepteur gitr à chaîne unique
WO2017102010A1 (fr) *	2015-12-17	2017-06-22	Biontech Rna Pharmaceuticals Gmbh	Nouvelles protéines de fusion à cytokine
US10821160B2 (en)	2016-03-01	2020-11-03	The Board Of Trustees Of The University Of Illinois	L-asparaginase variants and fusion proteins with reduced L-glutaminase activity and enhanced stability
CN108884142A (zh) *	2016-03-16	2018-11-23	梅里麦克制药股份有限公司	用于癌症治疗的工程化trail
US10501744B2 (en)	2016-05-04	2019-12-10	Indiana University Research And Technology Corporation	Presentation of bioactive proteins
TWI808055B (zh)	2016-05-11	2023-07-11	美商滬亞生物國際有限公司	Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh)	2016-05-11	2023-03-01	美商滬亞生物國際有限公司	Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
KR20190017804A (ko) *	2016-06-13	2019-02-20	메리맥 파마슈티컬즈, 인크.	환자를 선별하고 trail-기반 치료제 또는 사멸 수용체 효능제로 치료하는 방법
EP3360898A1 (fr)	2017-02-14	2018-08-15	Boehringer Ingelheim International GmbH	Molécules bispécifiques présentant une immunoréactivité par rapport à tnf-related apoptosis-inducing ligand receptor 2 et à cadherin 17 pour le traitement du cancer
AU2018313253B2 (en)	2017-08-11	2024-09-26	The Board Of Trustees Of The University Of Illinois	Truncated guinea pig L-asparaginase variants and methods of use
TW202002952A (zh) *	2018-03-15	2020-01-16	美商艾伯維有限公司	用於治療胰臟癌之abbv-621與抗癌劑之組合
WO2019178438A1 (fr) *	2018-03-15	2019-09-19	Abbvie Inc.	Abbv-621 en combinaison avec des agents anticancéreux pour le traitement du cancer
CN115836084A (zh)	2020-05-15	2023-03-21	阿珀吉尼科斯股份公司	多特异性免疫调节剂
AU2022281108A1 (en)	2021-05-28	2023-12-14	Julius-Maximilians-Universität Würzburg	Recombinant proteinaceous binding molecules
WO2023088876A1 (fr)	2021-11-16	2023-05-25	Apogenix Ag	Modulateurs immunitaires multi-spécifiques

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR025984A1 (es)	1999-10-07	2002-12-26	Maxygen Aps	Polipeptidos oligomericos de cadena simple
DE19963859A1 (de)	1999-12-30	2001-07-12	Apotech Res & Dev Ltd	Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2314199A1 (fr)	2000-07-21	2002-01-21	Robert Simoneau	Puce c
ES2311560T3 (es) *	2000-12-07	2009-02-16	Eli Lilly And Company	Proteinas de fusion glp-1.
US7317091B2 (en)	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
US7538088B2 (en)	2002-04-26	2009-05-26	California Institute Of Technology	Method for inhibiting angiogenesis by administration of the extracellular domain of D1-1 polypeptide
DE102004014983A1 (de)	2004-03-26	2005-10-20	Univ Stuttgart	Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US20060188498A1 (en) *	2005-02-18	2006-08-24	Genentech, Inc.	Methods of using death receptor agonists and EGFR inhibitors
ATE445644T1 (de) *	2005-04-15	2009-10-15	Rappaport Family Inst For Res	Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten
US8008443B2 (en)	2005-04-26	2011-08-30	Medimmune, Llc	Modulation of antibody effector function by hinge domain engineering
EP1894940A1 (fr)	2006-08-28	2008-03-05	Apogenix GmbH	Protéines de fusion de la superfamille TNF
ES2657801T3 (es)	2007-07-10	2018-03-06	Apogenix Ag	Proteínas de fusión de colectina de la superfamilia de TNF
EP3002299A1 (fr)	2008-06-03	2016-04-06	AbbVie Inc.	Immunoglobulines à deux domaines variables et leurs utilisations
EP3103875A1 (fr)	2008-07-21	2016-12-14	Apogenix AG	Molécules à chaîne unique tnfsf
WO2010033315A1 (fr) *	2008-09-22	2010-03-25	Amgen Inc.	Procédé de traitement
WO2010042890A2 (fr) *	2008-10-10	2010-04-15	Anaphore, Inc.	Polypeptides qui se lient à trail-ri et trail-r2
ES2593049T3 (es)	2009-01-09	2016-12-05	Apogenix Ag	Proteínas de fusión que forman trímeros
BRPI1006998A2 (pt) *	2009-01-23	2015-08-25	Biogen Idec Inc	Polipeptídeos fc estabilizados com função efetora reduzida e métodos de uso
JP2013514795A (ja) *	2009-12-22	2013-05-02	ノバルティスアーゲー	治療における使用のための四価ｃｄ４７抗体定常領域融合タンパク質
CA2796010C (fr) *	2010-04-13	2020-05-12	Medimmune, Llc	Echafaudages multimeres specifiques de trail r2
AU2012356894B2 (en)	2011-12-23	2018-01-18	Araris Biotech Ltd.	Enzymatic conjugation of polypeptides
CA2877989C (fr) *	2012-07-18	2021-05-25	Apogenix Gmbh	Variants cd95-fc raccourcis

2012
- 2012-11-06 NO NO12790406A patent/NO2776305T3/no unknown
2015
- 2015-04-23 ES ES15721089.9T patent/ES2672368T3/es active Active
- 2015-04-23 TW TW109106778A patent/TWI747178B/zh not_active IP Right Cessation
- 2015-04-23 CA CA2946402A patent/CA2946402C/fr active Active
- 2015-04-23 US US14/694,358 patent/US9908927B2/en active Active
- 2015-04-23 SI SI201530223T patent/SI3134430T1/en unknown
- 2015-04-23 PL PL15721089T patent/PL3134430T3/pl unknown
- 2015-04-23 PH PH1/2020/500377A patent/PH12020500377A1/en unknown
- 2015-04-23 CN CN201580031858.7A patent/CN106459221B/zh not_active Expired - Fee Related
- 2015-04-23 SG SG11201608767XA patent/SG11201608767XA/en unknown
- 2015-04-23 SG SG10201806465TA patent/SG10201806465TA/en unknown
- 2015-04-23 KR KR1020167032819A patent/KR102079919B1/ko not_active Expired - Fee Related
- 2015-04-23 TR TR2018/06912T patent/TR201806912T4/tr unknown
- 2015-04-23 BR BR112016024515-6A patent/BR112016024515B1/pt not_active IP Right Cessation
- 2015-04-23 JP JP2016564068A patent/JP6523331B2/ja not_active Expired - Fee Related
- 2015-04-23 AR ARP150101224A patent/AR100168A1/es active IP Right Grant
- 2015-04-23 PT PT157210899T patent/PT3134430T/pt unknown
- 2015-04-23 KR KR1020197035100A patent/KR20190135546A/ko not_active Ceased
- 2015-04-23 SG SG10202111785VA patent/SG10202111785VA/en unknown
- 2015-04-23 UY UY0001036095A patent/UY36095A/es active IP Right Grant
- 2015-04-23 HU HUE15721089A patent/HUE038914T2/hu unknown
- 2015-04-23 RS RS20180450A patent/RS57153B1/sr unknown
- 2015-04-23 MA MA039770A patent/MA39770A/fr unknown
- 2015-04-23 HR HRP20180950TT patent/HRP20180950T1/hr unknown
- 2015-04-23 CN CN202010767219.XA patent/CN111718424A/zh active Pending
- 2015-04-23 AU AU2015249649A patent/AU2015249649B2/en not_active Ceased
- 2015-04-23 DK DK15721089.9T patent/DK3134430T3/en active
- 2015-04-23 CA CA3184067A patent/CA3184067A1/fr active Pending
- 2015-04-23 TW TW104113087A patent/TWI683825B/zh not_active IP Right Cessation
- 2015-04-23 MA MA045069A patent/MA45069A/fr unknown
- 2015-04-23 SM SM20180286T patent/SMT201800286T1/it unknown
- 2015-04-23 WO PCT/US2015/027270 patent/WO2015164588A1/fr not_active Ceased
- 2015-04-23 MX MX2016013858A patent/MX2016013858A/es active IP Right Grant
- 2015-04-23 UA UAA201611802A patent/UA118286C2/uk unknown
- 2015-04-23 PE PE2016002016A patent/PE20170299A1/es unknown
- 2015-04-23 LT LTEP15721089.9T patent/LT3134430T/lt unknown
- 2015-04-23 RU RU2016145608A patent/RU2699285C2/ru active
- 2015-04-23 CR CR20160516A patent/CR20160516A/es unknown
- 2015-04-23 EP EP18155146.6A patent/EP3366699A1/fr not_active Withdrawn
- 2015-04-23 MY MYPI2016703814A patent/MY181986A/en unknown
- 2015-04-23 EP EP15721089.9A patent/EP3134430B1/fr active Active
2016
- 2016-10-07 IL IL248244A patent/IL248244B/en active IP Right Grant
- 2016-10-19 PH PH12016502079A patent/PH12016502079A1/en unknown
- 2016-10-19 DO DO2016000284A patent/DOP2016000284A/es unknown
- 2016-10-21 CL CL2016002683A patent/CL2016002683A1/es unknown
- 2016-10-21 MX MX2019013587A patent/MX2019013587A/es unknown
- 2016-11-23 EC ECIEPI201689579A patent/ECSP16089579A/es unknown
2018
- 2018-02-02 US US15/887,509 patent/US20180222962A1/en not_active Abandoned
- 2018-05-25 CY CY20181100568T patent/CY1120281T1/el unknown
- 2018-11-30 AU AU2018271369A patent/AU2018271369B2/en not_active Ceased
2019
- 2019-04-24 JP JP2019082671A patent/JP6714751B2/ja not_active Expired - Fee Related
2020
- 2020-02-11 IL IL272612A patent/IL272612A/en unknown
- 2020-03-30 AU AU2020202247A patent/AU2020202247A1/en not_active Abandoned
- 2020-08-14 US US16/993,569 patent/US20210040178A1/en not_active Abandoned
2023
- 2023-07-14 US US18/352,769 patent/US20240174731A1/en not_active Abandoned
2024
- 2024-09-23 US US18/892,964 patent/US20250145688A1/en active Pending

Also Published As

Publication number	Publication date
PH12016502079B1 (en)	2016-12-19
AU2015249649A1 (en)	2016-11-10
IL272612A (en)	2020-03-31
IL248244A0 (en)	2016-11-30
KR20170012257A (ko)	2017-02-02
ECSP16089579A (es)	2018-05-31
SG10202111785VA (en)	2021-12-30
UA118286C2 (uk)	2018-12-26
CN106459221B (zh)	2020-09-01
SG11201608767XA (en)	2016-11-29
MX2016013858A (es)	2017-08-02
NZ725476A (en)	2023-09-29
EP3366699A1 (fr)	2018-08-29
MY181986A (en)	2021-01-18
SI3134430T1 (en)	2018-05-31
TW201620928A (zh)	2016-06-16
US20210040178A1 (en)	2021-02-11
AR100168A1 (es)	2016-09-14
DK3134430T3 (en)	2018-05-22
US20240174731A1 (en)	2024-05-30
SMT201800286T1 (it)	2018-07-17
IL248244B (en)	2020-03-31
TW202024123A (zh)	2020-07-01
JP6714751B2 (ja)	2020-06-24
BR112016024515B1 (pt)	2020-03-31
NO2776305T3 (fr)	2018-01-27
MX2019013587A (es)	2020-01-13
PH12016502079A1 (en)	2016-12-19
TWI747178B (zh)	2021-11-21
SG10201806465TA (en)	2018-08-30
KR20190135546A (ko)	2019-12-06
US20180222962A1 (en)	2018-08-09
KR102079919B1 (ko)	2020-02-24
JP2019162114A (ja)	2019-09-26
EP3134430B1 (fr)	2018-03-21
US20250145688A1 (en)	2025-05-08
WO2015164588A1 (fr)	2015-10-29
LT3134430T (lt)	2018-05-10
CA2946402A1 (fr)	2015-10-29
AU2018271369A1 (en)	2018-12-20
CA3184067A1 (fr)	2015-10-29
CN106459221A (zh)	2017-02-22
RU2016145608A (ru)	2018-05-28
CA2946402C (fr)	2023-02-28
MA39770A (fr)	2015-10-29
JP6523331B2 (ja)	2019-05-29
AU2015249649B2 (en)	2018-10-04
ES2672368T3 (es)	2018-06-14
CR20160516A (es)	2017-05-10
RS57153B1 (sr)	2018-07-31
TWI683825B (zh)	2020-02-01
US9908927B2 (en)	2018-03-06
EP3134430A1 (fr)	2017-03-01
UY36095A (es)	2015-10-30
CL2016002683A1 (es)	2017-07-07
DOP2016000284A (es)	2017-02-15
AU2018271369B2 (en)	2020-01-02
CN111718424A (zh)	2020-09-29
CY1120281T1 (el)	2019-07-10
RU2016145608A3 (fr)	2018-12-26
TR201806912T4 (tr)	2018-06-21
BR112016024515A2 (pt)	2017-10-10
AU2020202247A1 (en)	2020-04-23
PH12020500377A1 (en)	2022-11-14
US20150337027A1 (en)	2015-11-26
JP2017513503A (ja)	2017-06-01
RU2699285C2 (ru)	2019-09-04
PE20170299A1 (es)	2017-05-06
PT3134430T (pt)	2018-04-20
HRP20180950T1 (hr)	2018-08-10
PL3134430T3 (pl)	2018-08-31
HUE038914T2 (hu)	2018-12-28

Publication	Publication Date	Title
EP3650449A4 (fr)	2021-04-07	Agoniste du récepteur fxr
IL272612A (en)	2020-03-31	Single-chain proteins are agonists of the TRAIL receptor
IL251963A0 (en)	2017-06-29	Anti-pd-1 antibodies
EP3352472A4 (fr)	2019-01-30	Récepteur
DK3344654T3 (da)	2021-01-18	Anti-lag-3-antistoffer
PL3417725T3 (pl)	2021-10-18	Fajka wodna
EP3319984C0 (fr)	2026-03-11	Anticorps de liaison tau
EP3347035A4 (fr)	2019-05-01	Peptides localisant le cartilage
DK3350218T5 (da)	2024-09-30	Polyomavirus-neutraliserende antistoffer
DK3211743T3 (da)	2019-12-16	Ø-til-netværk-omskiftningsfremgangsmåde
EP3319983C0 (fr)	2026-01-28	Anticorps de liaison tau
HUE060878T2 (hu)	2023-04-28	Anti-transztiretin antitestek
DK3250593T3 (da)	2022-08-22	Anti-transthyretin-antistoffer
DK3143037T3 (da)	2021-09-20	Alpha4beta7-integrin-thioether-peptidantagonister
PT3215530T (pt)	2019-11-21	Anticorpos de il-6 melhorados
LT3684813T (lt)	2026-01-26	Agonistiniai cd40 antikūnai
DK3702450T3 (da)	2024-07-15	Protein
EP3353793A4 (fr)	2019-05-08	Récepteur rf
HRP20182029T1 (hr)	2019-02-08	Uti-fuzijski proteini
HUE054148T2 (hu)	2021-08-30	Anti-ORAI1 antitest
EP3160502B1 (fr)	2026-05-20	Anticorps bispécifiques anti-il4-il13
LT3126391T (lt)	2020-02-10	Hpa-1a antikūnai
DK3099793T3 (da)	2020-03-16	Protein
LT3628731T (lt)	2021-08-10	Naujas antipresepsino antikūnas
EP3418079A4 (fr)	2019-10-16	Récepteur